Intuitive Surgical, Inc. (ISRG)
Manufacturer of da Vinci Surgical System, an advanced surgical system that provides the surgeon with range of motion and fine tissue control, previously possible only with open surgery while also allowing the surgeon to work through small ports.
Recs
Expensive equipment that healthcare cannot afford. Pricing and profits will come down with competition.
Recs
Look I love the Da Vinci technology and ISRG has done a great job with it, but this stock is not for the faint of heart. It is extremely volatile. I think it is a buy at $150 and below. I think a stock price of $150 would represent the true value of the business.
Recs
overpriced
Recs
ISRG looks very overbought right now. This is a great company, but the numbers, even optimistic ones, do not support the valuation.
Recs
Any man who is willing to put money into this company at this price is surely to underperform the market. The great results of this company have already been priced in.
Recs
Up too fast. Worst part of hospital spending cuts have yet to hit. Otherwise I'm a fan.
Recs
Overvalued compared to industry.
Recs
going down to 140 economy lol
Recs
Overvalued, for the moment.
Recs
With discretionary income being squeezed by high oil and food prices will people be willing to plunk down big bucks for cosmetic surgeries? I have to bet against it for the short term. If sales decrease by any significant % (15-20%) the shares will have to fall to a more reasonable valuation. March 2009 could see stock at $200. My only concern-- the wealthy are unaffected by rising costs and the poor don't understand the effects on their budget until after they have the procedure.
Recs
HighGain+ HighPE
Recs
Insider sale. There are other sectors where more money can be made.
Recs
Who has been waiting for this overvalued stock to come back down to some realisitc valuations? Tomorrow we are rewarded.
Recs
Overly optimistic expectations built into the price.
Recs
Looking like a head and shoulder top
Recs
Recs
GREAT COMPANY BUT OVERBOUGHT
Recs
The Robot does not offer significant enough advantage (that of better dexterity and 3D optics) over standard laparoscopic or thoracoscopic instruments to justify its steep costs. It's major drawback is a lack of tactile feedback and this takes away from its benefits. I don't see it becoming a standard of care until they make smaller and less expensive products (which would severely cut into margins). I'm extremely skeptical it will sustain a growth rate or its margins to justify the stock price.
Recs
This one is heading down. It has been bought up on hype and the correction is coming. Look to pick up around 285 or so
Recs
Way too overpriced. Hospitals will not have the kind of coin to foot the bill for this piece of equipment. It is a great technology but very difficult to afford.

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 33 1 2 Next »